Home / Market News / $LIVN

$LIVN news and market catalysts

The 9 most recent market catalysts affecting $LIVN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 2 high impact 7 bullish 1 bearish Medical Devices
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains LivaNova at Overweight and Raises Price Target to $120
Barclays has maintained its 'Overweight' rating on LivaNova PLC and raised its price target from $105 to $120. This 14.3% increase in the target price implies a significant 33.3% u…
Nov 4, 2026 Corporate Catalyst Bullish Impact 85
LivaNova Reports Third-Quarter 2026 Results and Raises Full-Year Guidance
LivaNova announced strong third-quarter 2026 results, with revenue increasing by nearly 10% and adjusted diluted EPS reaching $1.23. This performance led the company to raise its f…
Oct 23, 2026 Corporate Catalyst Bullish Impact 65
LivaNova Announces Publication of 36-Month CORE-VNS Study Results
LivaNova disclosed the publication of 36-month results from its CORE-VNS study, highlighting a 76% median reduction in seizure frequency for patients with drug-resistant epilepsy. …
Oct 7, 2026 Corporate Catalyst Neutral Impact 65
Barclays Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $105
Barclays analyst Christopher Pasquale initiated coverage on LivaNova (LIVN) with an 'Overweight' rating and set a price target of $105. This event is significant as it introduces a…
Sep 2, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90
This filing indicates that Piper Sandler analyst Adam Maeder has reaffirmed an 'Overweight' rating on LivaNova (LIVN) and raised the price target from $87 to $90. This is a positiv…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on LivaNova, Raises Price Target to $93
Needham analyst Mike Matson maintained a 'Buy' rating on LivaNova (LIVN) and raised the price target from $81 to $93. This upgrade in price target indicates increased confidence fr…
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
LivaNova shares are trading lower after the company reported Q2 financial results, with weakness tied to declining operating income and reduced cash flow guidance.
The headline points to a direct corporate catalyst: LivaNova's disappointing Q2 financial results. Declining operating income and reduced cash flow guidance are critical indicators…
Aug 5, 2026 Corporate Catalyst Bullish Impact 92
LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate
LivaNova announced its Q2 earnings, reporting adjusted EPS of $1.26, which surpassed the analyst consensus of $1.10 by 14.55%. Additionally, the company's sales reached $390.6 mill…
Jul 15, 2026 Corporate Catalyst Bullish Impact 60
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $95
Mizuho analyst Anthony Petrone has maintained an 'Outperform' rating on LivaNova (LIVN) and raised the price target from $90 to $95. This action signals a positive outlook from a p…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.